Klajdi, our CEO at Luminary Group, will be attending the World Drug Safety Congress Europe from 09-10 October. If you'd like to grab 5-10 minutes with Klajdi to discuss potential collaborations or share insights, feel free to reach out and connect. It’s a great opportunity to explore new ideas and strengthen relationships in the industry. Luminary Group has positioned itself as a leader in the consulting space, specializing in placing top executives and offering tailored commercial, operational, and outsourcing solutions for pharmaceutical companies in niche areas such as pharmacovigilance and regulatory affairs across Europe, the USA, and APAC. We are excited to meet with our industry partners and peers at the event. Looking forward to seeing you all there! #WDSC #pharmacovigilance #pharma #regulatory #compliance #pv #lifescience #healthcare #consulting #amsterdam #netherlands #worlddrugsafetyeurope #worlddrugsafety
About us
Luminary Group is a international business consultancy focused on the life sciences and pharmaceutical sectors. Headquartered at St Magnus House, 3 Lower Thames Street, Central London, EC3R 6HD, we deliver comprehensive services in three key areas. Luminary Executive: Specializing in C-suite to Director-level appointments, we identify top talent for positions including Chairman, Board members, CEO, CCO, COO, AVP to Director level. Luminary Staffing: We provide both temporary and permanent staffing solutions tailored to meet the commercial, project management, medical, biometrics, software and operational needs of our clients. Luminary Consulting: Offering high-quality services in medical writing, regulatory affairs, quality assurance, pharmacovigilance, and data science for the medical and pharmaceutical industries. We also provide strategic partnerships to accelerate growth through Recruitment Process Outsourcing (RPO) and Functional Service Provider (FSP) services. Lastly, our advisory services assist in data partnerships, leveraging our extensive network of leading RWE, RWD, and AI enterprises across the US and Europe, and provide guidance for business collaborations with biotechnology firms and navigating mergers and acquisitions. Our expertise includes Real World Evidence (RWE), eClinical solutions, Artificial Intelligence (AI), Biotechnology, Consulting, and Medical Devices. Operating globally with a presence in the USA, Europe, APAC, and the Middle East, we take pride in our exclusive talent pool, ranging from C-Suite to Managerial levels, and our partnerships with returning clients and candidates. Our collaborations extend across a diverse range of companies, from corporate giants to innovative start-ups. For more information, please visit our website: www.luminarygroup.co.uk.
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
City of London , GB
-
4th St N, STE 300
7901
St. Petersburg, FL , 33702, US
Employees at Luminary Group
Updates
-
𝗔𝗳𝘁𝗲𝗿 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝗶𝗻𝗴 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰𝘀 𝘄𝗶𝘁𝗵 𝗔𝗜, 𝗮 𝟯𝟭-𝘆𝗲𝗮𝗿-𝗼𝗹𝗱 𝗳𝗶𝗿𝘀𝘁-𝘁𝗶𝗺𝗲 𝗖𝗘𝗢 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟭𝟳𝗠 𝘁𝗼 𝗳𝗶𝗴𝗵𝘁 𝗮𝗴𝗶𝗻𝗴 Jim Collins the famed MIT professor and a godfather of the synthetic biology field, describes Felix Wong as one of the most talented researchers to … https://lnkd.in/d73uJzAm
-
𝗨𝗞 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗯𝗮𝗴𝘀 $𝟰𝟯𝗠 𝗶𝗻 𝗦𝗲𝗿𝗶𝗲𝘀 𝗔 𝘁𝗼 𝗺𝗼𝘃𝗲 𝗛𝘂𝗻𝘁𝗶𝗻𝗴𝘁𝗼𝗻'𝘀 𝗱𝗿𝘂𝗴 𝗶𝗻𝘁𝗼 𝗳𝗶𝗿𝘀𝘁 𝗵𝘂𝗺𝗮𝗻 𝘀𝘁𝘂𝗱𝘆 LoQus23 Therapeutics Ltd has secured £35 million ($43 million) in a Series A fundraise backed by the venture arm of Novartis India to help advance its lead … https://lnkd.in/dwcKeiVR
UK biotech bags $43M in Series A to move Huntington's drug into first human study
endpts.com
-
𝗖𝗔𝗠𝗣𝟰, 𝗽𝗿𝗲𝗽𝗮𝗿𝗶𝗻𝗴 𝗳𝗼𝗿 𝗜𝗣𝗢, 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝘄𝗶𝘁𝗵 𝗕𝗶𝗼𝗠𝗮𝗿𝗶𝗻 Regulatory Pharma Net - RPN startup CAMP4 Therapeutics has inked another collaboration deal as it prepares for an initial public offering. The Cambridge, MA-based startup has lined up … https://lnkd.in/daxaNzur
CAMP4, preparing for IPO, announces partnership with BioMarin
endpts.com
-
𝗥𝗼𝗻 𝗥𝗲𝗻𝗮𝘂𝗱'𝘀 𝗻𝗲𝘄 𝗼𝗯𝗲𝘀𝗶𝘁𝘆 𝗯𝗶𝗼𝘁𝗲𝗰𝗵, 𝗞𝗮𝗶𝗹𝗲𝗿𝗮, 𝗵𝗮𝘀 $𝟰𝟬𝟬𝗠 𝘁𝗼 𝗴𝗼 𝘀𝘁𝗿𝗮𝗶𝗴𝗵𝘁 𝘁𝗼 𝗣𝗵𝗮𝘀𝗲 𝟯 There’s major money behind efforts to speed the next significant obesity company to the market. First, it was Metsera, which launched in April with …Ron Renaud,Kailera Therapeutics https://lnkd.in/dE6qFU7g
Ron Renaud's new obesity biotech, Kailera, has $400M to go straight to Phase 3
endpts.com
-
𝗙𝗗𝗔 𝗽𝗹𝗲𝗱𝗴𝗲𝘀 𝘁𝗼 𝘁𝗮𝗸𝗲 𝗻𝗲𝘅𝘁 𝘀𝘁𝗲𝗽𝘀 𝗼𝗻 𝗮𝗱𝘃𝗶𝘀𝗼𝗿𝘆 𝗰𝗼𝗺𝗺𝗶𝘁𝘁𝗲𝗲 𝗰𝗵𝗮𝗻𝗴𝗲𝘀 As the potential end of Robert Califf time as FDA commissioner nears, he and a key deputy are continuing to push forward with changes to … https://lnkd.in/dWSYxhP4
FDA pledges to take next steps on advisory committee changes
endpts.com
-
𝗨𝗻𝘃𝗲𝗹𝗹𝗶𝗻𝗴 𝗥𝗲𝗰𝗲𝗻𝘁 𝗙𝘂𝗻𝗱𝗶𝗻𝗴,𝗠&𝗔 𝗮𝗻𝗱 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀-𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟰 ARCH Venture Partners raises $3B biotech fund to invest in innovative science. BioAge Labs raises $198M in IPO to develop drug-enhancing weight loss medications. Vicebio raises $100M to develop cost-effective vaccines targeting viral proteins in prefusion shape. Sanofi reportedly receives bids over €15B for its consumer health unit from CD&R LLP and PAI Partners. Pentagono - U.S.A commits $500M annually to women's health research on arthritis, chronic fatigue, and heart issues. Bavarian Nordic secures $63M BARDA order for additional doses of its mpox vaccine Jynneos. Genespire raises $52M to develop injectable gene therapies for rare pediatric conditions. Emergent BioSolutions secures $67.4M to supply TEMBEXA for U.S. smallpox preparedness; shares rise 22%. Nuvalent, Inc. raises approximately $575M through public offering to fund targeted cancer therapies. Organon to acquire Dermavant Sciences for $175M upfront, gaining psoriasis cream VTAMA® (tapinarof) cream, 1% HCP and potential eczema approval. Novo Nordisk and NanoVation Therapeutics™ sign $600M deal for rare and cardiometabolic disease therapies. Nura Bio secures $68M and new CEO to advance neuroprotective drugs for neurodegenerative diseases. GC Therapeutics raises $75M to develop 'supercell' therapies from stem cells, aiming for faster treatments. Bicara Therapeutics, Zenas BioPharma, and MBX Biosciences, Inc. - raised over $700M in IPOs, signaling a rebound in biotech public offerings. Candid Therapeutics launches with $370M funding to develop antibody drugs for inflammatory disease.
-
𝗚𝗮𝗿𝘆 𝗚𝗹𝗶𝗰𝗸 𝗴𝗲𝘁𝘀 $𝟮𝟳𝗠 𝘁𝗼 𝗹𝗲𝗮𝗽 𝗯𝗮𝗰𝗸 𝗶𝗻𝘁𝗼 𝗶𝗺𝗺𝘂𝗻𝗼-𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗥&𝗗 𝘄𝗶𝘁𝗵 𝗡𝗼𝘃𝗮𝗿𝘁𝗶𝘀, 𝗔𝘁𝗹𝗮𝘀 𝗮𝗻𝗱 𝗔𝗯𝗶𝗻𝗴𝘄𝗼𝗿𝘁𝗵 𝗶𝗻 𝗵𝗶𝘀 𝗰𝗼𝗿𝗻𝗲𝗿 Gary Glick didn’t specifically intend to start a new biotech after he left Lycera, where he was the founder and CSO, a little more … https://lnkd.in/d83Z2JFS
Gary Glick gets $27M to leap back into immuno-oncology R&D with Novartis, Atlas and Abingworth in his corner
endpts.com
-
𝗘𝗻𝗚𝗲𝗻𝗲 𝘂𝗻𝘃𝗲𝗶𝗹𝘀 𝗳𝗶𝗿𝘀𝘁 𝘀𝗲𝘁 𝗼𝗳 𝗽𝗶𝘃𝗼𝘁𝗮𝗹 𝗱𝗮𝘁𝗮 𝗳𝗼𝗿 𝗡𝗠𝗜𝗕𝗖 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 A small US and Canadian gene therapy biotech has released a look at data from its experimental bladder cancer treatment, hoping to enter a field …Ron Cooper enGene https://lnkd.in/dFqbmStD pivotal-data-for-nmibc-therapy/
EnGene unveils first set of pivotal data for NMIBC therapy
endpts.com
-
𝗙𝗗𝗔 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝘀 𝗗𝘂𝗽𝗶𝘅𝗲𝗻𝘁 𝗶𝗻 𝗖𝗢𝗣𝗗, 𝗼𝗽𝗲𝗻𝗶𝗻𝗴 ‘𝗻𝗲𝘅𝘁 𝗰𝗵𝗮𝗽𝘁𝗲𝗿’ 𝗳𝗼𝗿 𝗦𝗮𝗻𝗼𝗳𝗶 𝗮𝗻𝗱 𝗥𝗲𝗴𝗲𝗻𝗲𝗿𝗼𝗻’𝘀 𝗯𝗲𝘀𝘁𝘀𝗲𝗹𝗹𝗲𝗿 The biggest drug driving Sanofi's and Regeneron Pharmaceuticals, Inc. businesses is about to get a bit bigger. On Friday, the FDA approved DUPIXENT® (dupilumab) HCP as an add-on to … https://lnkd.in/d_3DUDSY
FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller
endpts.com